Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease

Show simplified metadata
dc.contributor.affiliationThe Chinese University of Hong Kong; Yonsei University College of Medicine; Shanghai Jiao Tong University; Royal Free Hospital; University College London; University of Palermo; University of Turin; Yokohama City University Graduate School of Medicine; The First Affiliated Hospital of Wenzhou Medical University; Karolinska Institutet; Karolinska University Hospital; Angers University Hospital; Angers University; Hospital Universitario Puerta de Hierro Majadahonda; Singapore General Hospital; University of Malaya; Virgen del Rocío University Hospital; Virginia Commonwealth University School of Medicine; Echosens; King's College London; King's College Hospital; Xinhua Hospital; Shanghai Jiao Tong University; Université Paris Cité; Assistance Publique-Hôpitaux de Paris; Harvard Medical School; Wenzhou Medical University; University Hospitals Birmingham NHS Foundation Trust; University of Birmingham; Yonsei University College of Medicine
dc.contributor.authorLai, Jimmy Che-To
dc.contributor.authorYang, Boyu
dc.contributor.authorLee, Hye Won
dc.contributor.authorLin, Huapeng
dc.contributor.authorTsochatzis, Emmanuel A
dc.contributor.authorPetta, Salvatore
dc.contributor.authorBugianesi, Elisabetta
dc.contributor.authorYoneda, Masato
dc.contributor.authorZheng, Ming-Hua
dc.contributor.authorHagström, Hannes
dc.contributor.authorBoursier, Jerome
dc.contributor.authorCalleja, Jose Luis
dc.contributor.authorGoh, George Boon-Bee
dc.contributor.authorChan, Wah-Kheong
dc.contributor.authorGallego-Duràn, Rocìo
dc.contributor.authorSanyal, Arun J
dc.contributor.authorde Lédinghen, Victor
dc.contributor.authorNewsome, Philip Noel
dc.contributor.authorFan, Jian-Gao
dc.contributor.authorCastera, Laurent
dc.contributor.authorLai, Michelle
dc.contributor.authorFournier-Poizat, Céline
dc.contributor.authorWong, Grace Lai-Hung
dc.contributor.authorPennisi, Grazia
dc.contributor.authorArmandi, Angelo
dc.contributor.authorNakajima, Atsushi
dc.contributor.authorLiu, Wen-Yue
dc.contributor.authorShang, Ying
dc.contributor.authorSaint-Loup, Marc de
dc.contributor.authorLlop, Elba
dc.contributor.authorTeh, Kevin Kim Jun
dc.contributor.authorLara-Romero, Carmen
dc.contributor.authorAsgharpour, Amon
dc.contributor.authorMahgoub, Sara
dc.contributor.authorChan, Mandy Sau-Wai
dc.contributor.authorCanivet, Clemence M
dc.contributor.authorRomero-Gómez, Manuel
dc.contributor.authorKim, Seung Up
dc.contributor.authorWong, Vincent Wai-Sun
dc.contributor.authorYip, Terry Cheuk-Fung
dc.contributor.departmentHepatology
dc.contributor.departmentResearch and Development
dc.contributor.roleMedical and Dental
dc.contributor.trustauthorMahgoub, Sara
dc.date.accessioned2025-08-06T10:13:37Z
dc.date.available2025-08-06T10:13:37Z
dc.date.issued2025-06-20
dc.description.abstractBackground: Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over 30% of the general population and is the fastest growing cause of hepatocellular carcinoma (HCC). Current guidelines recommend HCC surveillance in patients with cirrhosis when annual HCC incidence exceeds 1% without specifying the role of non-invasive tests in patient selection. Objective: To define non-invasive test thresholds to select patients with MASLD for HCC surveillance. Design: A multicentre longitudinal study of adults with MASLD from 16 tertiary centres in the USA, Europe and Asia between February 2004 and January 2023. Primary outcome was incident HCC. Results: 12 950 patients had Fibrosis-4 index (FIB-4) and liver stiffness measurement (LSM) (mean age 51.7 years; 41.1% male). At a median follow-up of 47.7 (IQR 23.3-72.3) months, 109 (0.8%) developed HCC. FIB-4 was below the low cut-off (<1.3 if aged <65 years and <2.0 if aged ≥65 years), between the low cut-off and <2.67, 2.67 to <3.25, and ≥3.25 in 66.3%, 23.9%, 3.4% and 6.4% of patients; the corresponding annual HCC incidence was 0.07%, 0.17%, 0.77% and 1.18%. As a stand-alone test, the annual HCC incidence exceeded 0.2% for LSM ≥10 kPa and 1% for LSM ≥20 kPa. If LSM was performed as a second step only among patients with FIB-4 above the low cut-off, the annual HCC incidence exceeded 0.2% for LSM ≥10 kPa and 1% for LSM ≥15 kPa. Conclusion: HCC surveillance should be offered to patients with MASLD with FIB-4 ≥3.25 or LSM ≥20 kPa. When a two-step approach is adopted, LSM ≥15 kPa in patients with increased FIB-4 predicts a high HCC risk.
dc.identifier.citationLai JC, Yang B, Lee HW, Lin H, Tsochatzis EA, Petta S, Bugianesi E, Yoneda M, Zheng MH, Hagström H, Boursier J, Calleja JL, Goh GB, Chan WK, Gallego-Duràn R, Sanyal AJ, de Lédinghen V, Newsome PN, Fan JG, Castera L, Lai M, Fournier-Poizat C, Wong GL, Pennisi G, Armandi A, Nakajima A, Liu WY, Shang Y, Saint-Loup M, Llop E, Teh KKJ, Lara-Romero C, Asgharpour A, Mahgoub S, Chan MS, Canivet CM, Romero-Gómez M, Kim SU, Wong VW, Yip TC. Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease. Gut. 2025 Nov 10;74(12):2050-2057. doi: 10.1136/gutjnl-2025-334981.
dc.identifier.doi10.1136/gutjnl-2025-334981
dc.identifier.eissn1468-3288
dc.identifier.issn0017-5749
dc.identifier.other40541300
dc.identifier.piigutjnl-2025-334981
dc.identifier.pmid40541300
dc.identifier.urihttps://westmid.openrepository.com/handle/20.500.14200/8152
dc.language.isoen
dc.publisherBritish Medical Association
dc.relation.urlhttps://gut.bmj.com/
dc.rights© Author(s) (or their employer(s)) 2025. No commercial re-use. See rights and permissions. Published by BMJ Group.
dc.source.countryEngland
dc.source.journaltitleGut
dc.subjectGastroenterology
dc.subjectOncology. Pathology.
dc.titleNon-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease
dc.typeArticle
dspace.entity.typePublication
oa.grant.openaccessna
rioxxterms.versionNA
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.7 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
UHB Gastroenterology